Keith W. Pratz

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Keith W. Pratz
Apr 1, 2025, 09:37 | Blog
Roberta Demichelis: Thanks to all the professors who joined this first hematology congress at INCMNSZ
Roberta Demichelis, Acute Leukemia Clinic Coordinator at INCMNSZ, shared a post on X: "Thanks to…
Dec 23, 2024, 11:55 | Drugs
Talha Badar: Venetoclax and Azacitidine for elderly AML ineligible for intensive Induction
Talha Badar shared on X: “Brief overview of venetoclax+azacitidine for elderly AML ineligible for intensive…
Dec 6, 2024, 15:22 | Insight
The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML
Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on…
Nov 8, 2024, 14:30 | Insight
Keith W Pratz: The utility of post remission use of GCSF in the VIALE-A trial
Keith W Pratz, Director of Leukemia, Hospital of University of Pennsylvania Philadelphia, shared his recent…
Aug 14, 2024, 07:20 | Drugs
Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax
Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on…
Aug 10, 2024, 03:56 | Insight
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia
Bichoy Gabra, Oncology Infusion Pharmacy Services Manager at Moffitt Cancer Center, shared on X: "Many…
Jul 25, 2024, 21:01 | Blog
Caner Saygin: A testament to the fact that flow MRD is insufficient for making treatment decisions in ALL
Caner Saygin, Assistant Professor of Medicine at University of Chicago, shared a post by NEJM, on X:…
All: 7 Posts: 1 - 100
Special Coverage